Can finerenone protect the kidneys of people who don’t have diabetes?
Yes. In this large Phase III trial, finerenone slowed the loss of kidney function in adults who had chronic kidney disease but no diabetes. Over about 32 months, people on the drug kept more of their kidney function than people on a placebo.
Chronic kidney disease, or CKD, means the kidneys slowly lose their ability to filter waste from the blood. For years, doctors knew finerenone helped protect the kidneys of people with diabetes. But most people did not know if it would help the millions of people who have CKD without diabetes. This trial, called FIND-CKD, was built to answer that exact question.
What the data show
Doctors measure kidney function with a number called eGFR. A higher eGFR means healthier kidneys, and a falling eGFR means the kidneys are wearing down. In this trial, finerenone slowed that fall in eGFR over roughly 32 months compared with placebo. In plain terms, people who took the drug held onto more of their kidney function as time passed.
The benefit went beyond the kidneys alone. Finerenone also lowered the chance of a serious combined outcome. This included kidney failure, a large and lasting drop in kidney function, hospital stays for heart failure, or death from heart and blood vessel problems. Bringing down that whole group of bad outcomes is a strong signal that the drug helps the body in more than one way.
Dr. Kumar’s Take
What I find exciting here is who this trial was for. Most kidney drug research has focused on people with diabetes, which left a huge group of patients in a gray zone. Many of my patients have CKD from high blood pressure or other causes, not diabetes, and they have asked me for years what they can do. This trial finally gives us real evidence for them.
I want to be honest about the limits too. Finerenone is not a cure, and it does not reverse damage that is already done. It slows the decline, which is meaningful but not magic. The drug can also raise potassium levels in the blood, so anyone taking it needs regular blood tests. Still, having a proven option for non-diabetic CKD is a real step forward.
Study Snapshot
FIND-CKD was a Phase III trial, which is the large and rigorous stage of testing before a drug earns wider approval for a new use. It was randomized and placebo-controlled, the gold standard in medicine. That means people were randomly sorted into two groups, and one group got a placebo, a dummy pill with no active drug. This design helps make sure the results come from finerenone and not from chance or wishful thinking.
The people in the trial were adults with chronic kidney disease who did not have diabetes. Researchers followed them for about 32 months, which is nearly three years. Over that long stretch, the team tracked how fast kidney function fell and counted serious health events in both groups.
Why this matters
CKD is common and quietly dangerous. It often has no symptoms until it is advanced, and it raises the risk of heart attacks, strokes, and early death. People with non-diabetic CKD make up a large share of all kidney disease, yet they have had fewer proven treatment options than people with diabetes.
By showing that finerenone helps this group, the trial widens the door to a treatment that was once limited to diabetic patients. That could change how doctors think about protecting kidneys across the board, not just in one type of patient.
Practical Takeaways
- If you have chronic kidney disease without diabetes, ask your doctor whether finerenone is a reasonable option for you, since this trial now provides direct evidence for your situation.
- Expect regular blood tests if you start finerenone, because the drug can raise potassium levels and your doctor will want to keep that in a safe range.
- Keep treating the root causes of your kidney disease, such as high blood pressure, since finerenone works best alongside good control of those underlying problems.
- Do not stop or change any current kidney or heart medication on your own, as finerenone is meant to add to your care, not replace your existing plan.
Related Studies and Research
- Chronic kidney disease has doubled and is now a top killer
- Creatine for type 2 diabetes: a placebo-controlled trial
- Does rosuvastatin prevent heart disease in healthy people with intermediate risk? A look at the HOPE-3 trial
- Adderall and heart risk: what a Mayo Clinic trial found
FAQs
What is finerenone and how does it work?
Finerenone is a prescription drug that blocks a hormone signal linked to inflammation and scarring in the kidneys and heart. By calming that process, it helps protect these organs from slow damage over time. It belongs to a newer class of drugs designed to be more targeted than older medicines that work in a similar area. In this trial, that protection showed up as slower loss of kidney function and fewer serious heart and kidney events.
Is finerenone only for people with diabetes?
Not anymore, based on this trial. For years, the strongest evidence for finerenone came from people who had both diabetes and kidney disease. The FIND-CKD trial tested it in adults who had chronic kidney disease but no diabetes, and it still slowed kidney decline. This suggests the drug can help a much wider group of kidney patients than doctors could confidently treat with it before.
What are the main risks of taking finerenone?
The most discussed risk is high potassium in the blood, a condition that can affect heart rhythm if it climbs too far. That is why people on finerenone usually get regular blood tests to keep potassium in a safe zone. Your doctor will weigh your own risk factors, including your kidney numbers and other medications, before starting the drug. Anyone considering it should have a clear conversation about monitoring and what symptoms to watch for.
Bottom Line
For the first time in a large Phase III trial, finerenone slowed the decline of kidney function in people who have chronic kidney disease but no diabetes. Over roughly 32 months, it also cut the risk of a serious mix of kidney failure, sharp drops in kidney function, heart failure hospital stays, and cardiovascular death. By extending a proven benefit to non-diabetic patients, this trial gives doctors and a very large group of people a real new tool to protect their kidneys.
